{"id":793322,"date":"2026-03-02T16:19:03","date_gmt":"2026-03-02T16:19:03","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=793322"},"modified":"2026-03-02T16:19:03","modified_gmt":"2026-03-02T16:19:03","slug":"menkes-disease-market-forecast-2034-fda-approvals-competitive-landscape-usd-79-million-market-size-in-2023-177-diagnosed-cases-clinical-pipeline-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/menkes-disease-market-forecast-2034-fda-approvals-competitive-landscape-usd-79-million-market-size-in-2023-177-diagnosed-cases-clinical-pipeline-delveinsight_793322.html","title":{"rendered":"Menkes Disease Market Forecast 2034: FDA Approvals, Competitive Landscape, USD 7.9 Million Market Size in 2023, 177 Diagnosed Cases, &#038; Clinical Pipeline | DelveInsight"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/upload\/2026\/03\/1772369486.jpg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Menkes Disease Market Forecast 2034: FDA Approvals, Competitive Landscape, USD 7.9 Million Market Size in 2023, 177 Diagnosed Cases, &amp; Clinical Pipeline | DelveInsight\" src=\"https:\/\/www.abnewswire.com\/upload\/2026\/03\/1772369486.jpg\" alt=\"Menkes Disease Market Forecast 2034: FDA Approvals, Competitive Landscape, USD 7.9 Million Market Size in 2023, 177 Diagnosed Cases, &amp; Clinical Pipeline | DelveInsight\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Menkes Disease Market<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">Menkes Disease companies working in the market are Cyprium Therapeutics and Sentynl Therapeutics, and others.<\/div>\n<p style=\"text-align: justify;\">In 2023, the Menkes disease market remained limited in size but demonstrated steady progression. The United States dominated the 7MM, contributing close to USD 7 million in revenue and is anticipated to witness further growth by 2034. Collectively, the total market across the seven major markets reached nearly USD 7.9 million, primarily supported by standard-of-care treatment approaches.<\/p>\n<p style=\"text-align: justify;\">The number of diagnosed cases is forecasted to rise, driven by advancements in genetic diagnostics, broader newborn screening initiatives, increased disease awareness, improved patient survival, and underlying genetic as well as environmental influences. In 2023, the United States accounted for nearly 54% of diagnosed cases, followed by Japan at 11%, while France held the highest proportion within Europe at 9%. Although prevalence is gradually increasing &#8211; with about 177 diagnosed cases reported across the 7MM in 2023, substantial unmet needs persist due to the absence of widely available, disease-specific approved therapies for Menkes disease.<\/p>\n<p style=\"text-align: justify;\">DelveInsight&#8217;s &#8220;<strong>Menkes Disease Market Insights, Epidemiology, and Market Forecast-2034<\/strong>&#8221; report delivers an in-depth understanding of Menkes Disease, historical and forecasted epidemiology as well as the Menkes Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.<\/p>\n<p style=\"text-align: justify;\">The Menkes Disease market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Menkes Disease market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Menkes Disease treatment practice\/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Menkes Disease market.<\/p>\n<p style=\"text-align: justify;\"><strong>Request for a Free Sample Report @ <\/strong><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/menkes-disease-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Menkes Disease Market Forecast<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Some facts of the Menkes disease report are:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>In 2023, the market size of Menkes Disease was highest in the US among the 7MM accounting for approximately USD 7 million that is further expected to increase by 2034.<\/li>\n<li>The overall market was covered by Standard of Care, making up the total Menkes Disease market of around USD 7.9 million in 2023, in the 7MM.<\/li>\n<li>Menkes Disease companies working in the market are &#8211; Cyprium Therapeutics and Sentynl Therapeutics, and others.<\/li>\n<li>As per DelveInsight&rsquo;s assessment, in 2023, nearly 177 diagnosed prevalent cases of Menkes Disease were estimated in the 7MM. These cases are anticipated to increase by 2034. The US accounted for the highest cases.<\/li>\n<li>In January 2026, Zydus Lifesciences has received FDA approval for Zycubo&reg;, establishing it as the first approved therapy in the United States for Menkes disease treatment. The drug has shown significant survival improvement in clinical studies, representing a major breakthrough in rare disease therapeutics and addressing critical unmet medical needs for patients with this genetic disorder.<\/li>\n<li>In January 2026, Sentynl Therapeutics announced that the U.S. Food and Drug Administration (FDA) has approved Zycubo (copper histidinate) injection as the first FDA-approved treatment for Menkes disease in pediatric patients. Zycubo is a subcutaneous copper replacement therapy designed to bypass the genetic defect that prevents intestinal copper absorption, enabling improved copper utilization in the body.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Menkes Disease Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Menkes disease is a rare, inherited <strong>neurodegenerative disorder<\/strong> caused by mutations in the <strong>ATP7A gene<\/strong>, leading to impaired copper absorption and distribution in the body. The disease primarily affects <strong>infants and young children<\/strong>, with symptoms typically appearing within the first few months of life. Clinical features include <strong>seizures, developmental delay, failure to thrive, hypotonia, characteristic kinky hair, and progressive neurological deterioration<\/strong>. Menkes disease also affects connective tissue, blood vessels, bones, and the nervous system. Without early treatment, the condition is often <strong>fatal in early childhood<\/strong>, highlighting a significant unmet medical need despite advances in diagnosis and care.<\/p>\n<p style=\"text-align: justify;\"><strong>Learn more about <\/strong><strong>Menkes Disease, t<\/strong><strong>reatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ <\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/menkes-disease-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>https:\/\/www.delveinsight.com\/sample-request\/menkes-disease-market<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\"><strong>Menkes Disease Market Outlook<\/strong><\/p>\n<p style=\"text-align: justify;\">In 2023, the total Menkes disease market across the <strong>7MM<\/strong> was valued at approximately <strong>USD 7.9 million<\/strong> and is projected to grow steadily through 2034. Market expansion will be supported by improved diagnosis, rising awareness, and the expected launch of targeted therapy, with <strong>France leading EU market share<\/strong>.<\/p>\n<p style=\"text-align: justify;\">Disorders of copper homeostasis have been recognized for decades and are linked to serious human diseases across the lifespan. Menkes disease, also known as kinky hair disease, is a rare, rapidly progressive neurodegenerative disorder of infancy characterized by seizures, developmental regression, failure to thrive, and distinctive hair abnormalities. Disease progression is often unpredictable and aggressive, and prognosis remains poor. Without access to copper replacement therapy, survival typically does not extend beyond 3.5 years.<\/p>\n<p style=\"text-align: justify;\">Current management relies on standard-of-care approaches, including off-label copper supplements such as copper histidine or copper chloride, along with antiepileptic drugs and supportive therapies. Despite these interventions, there is no approved targeted treatment for Menkes disease, underscoring a significant unmet medical need.<\/p>\n<p style=\"text-align: justify;\">Advances in therapeutic development are opening new opportunities, with <strong>CUTX-101<\/strong> emerging as the most promising candidate in the clinical pipeline. Its anticipated approval is expected to positively impact patient outcomes and drive market growth, especially alongside increased awareness and early disease screening.<\/p>\n<p style=\"text-align: justify;\"><strong>Request a sample and discover more about the report offerings at:<\/strong><strong> <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/menkes-disease-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/menkes-disease-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Menkes Disease Epidemiology<\/strong><\/p>\n<p style=\"text-align: justify;\">In <strong>2023<\/strong>, an estimated <strong>177 diagnosed prevalent cases of Menkes disease<\/strong> were reported across the <strong>7MM<\/strong>, with prevalence expected to rise by <strong>2034<\/strong>. The <strong>United States accounted for the largest share<\/strong> of cases. Within Europe, <strong>France led with 26%<\/strong> of diagnosed cases, followed by <strong>Germany and the UK at 24% each<\/strong>, while <strong>Spain reported the lowest share at 11%<\/strong>. <strong>Japan recorded approximately 19 diagnosed prevalent cases<\/strong> in the same year, highlighting the ultra-rare nature of the disease across all major markets.<\/p>\n<p style=\"text-align: justify;\"><strong>Menkes Disease Epidemiology Segmentation<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Prevalent Cases of Menkes Disease<\/li>\n<li>Diagnosed Prevalent Cases of Menkes Disease<\/li>\n<li>Severity-specific Diagnosed Prevalent Cases of Menkes Disease<\/li>\n<li>Etiology-specific Diagnosed Prevalent Cases of Menkes Disease<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Menkes Disease Pipeline Development Activities<\/strong><\/p>\n<p style=\"text-align: justify;\">The Menkes Disease report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Menkes Disease key players involved in developing targeted therapeutics.<\/p>\n<p style=\"text-align: justify;\"><strong>Request for a sample report to understand more about the Menkes Disease pipeline development activities at:<\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/menkes-disease-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>Menkes Disease Drugs and Therapies<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\"><strong>Menkes Disease Therapeutics Assessment<\/strong><\/p>\n<p style=\"text-align: justify;\">Major key companies are working proactively in the Menkes Disease Therapeutics market to develop novel therapies which will drive the Menkes Disease treatment markets in the upcoming years are Cyprium Therapeutics, Sentynl Therapeutics and several others.<\/p>\n<p style=\"text-align: justify;\"><strong>Request for free sample report @ <\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/menkes-disease-market?utm_source=openpr&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>Menkes Disease Clinical Trial and FDA Approval<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\"><strong>Menkes Disease Report Key Insights<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Menkes Disease Patient Population<\/p>\n<p style=\"text-align: justify;\">2. Menkes Disease Market Size and Trends<\/p>\n<p style=\"text-align: justify;\">3. Key Cross Competition in the Menkes Disease Market<\/p>\n<p style=\"text-align: justify;\">4. Menkes Disease Market Dynamics (Key Drivers and Barriers)<\/p>\n<p style=\"text-align: justify;\">5. Menkes Disease Market Opportunities<\/p>\n<p style=\"text-align: justify;\">6. Menkes Disease Therapeutic Approaches<\/p>\n<p style=\"text-align: justify;\">7. Menkes Disease Pipeline Analysis<\/p>\n<p style=\"text-align: justify;\">8. Menkes Disease Current Treatment Practices\/Algorithm<\/p>\n<p style=\"text-align: justify;\">9. Impact of Emerging Therapies on the Menkes Disease Market<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Key Insights<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary<\/p>\n<p style=\"text-align: justify;\">3. Menkes Disease Competitive Intelligence Analysis<\/p>\n<p style=\"text-align: justify;\">4. Menkes Disease Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">5. Menkes Disease Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\">6. Menkes Disease Patient Journey<\/p>\n<p style=\"text-align: justify;\">7. Menkes Disease Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\">8. Menkes Disease Treatment Algorithm, Current Treatment, and Medical Practices<\/p>\n<p style=\"text-align: justify;\">9. Menkes Disease Unmet Needs<\/p>\n<p style=\"text-align: justify;\">10. Key Endpoints of Menkes Disease Treatment<\/p>\n<p style=\"text-align: justify;\">11. Menkes Disease Marketed Products<\/p>\n<p style=\"text-align: justify;\">12. Menkes Disease Emerging Therapies<\/p>\n<p style=\"text-align: justify;\">13. Menkes Disease Seven Major Market Analysis<\/p>\n<p style=\"text-align: justify;\">14. Attribute Analysis<\/p>\n<p style=\"text-align: justify;\">15. Menkes Disease Market Outlook (7 major markets)<\/p>\n<p style=\"text-align: justify;\">16. Menkes Disease Access and Reimbursement Overview<\/p>\n<p style=\"text-align: justify;\">17. KOL Views on the Menkes Disease Market<\/p>\n<p style=\"text-align: justify;\">18. Menkes Disease Market Drivers<\/p>\n<p style=\"text-align: justify;\">19. Menkes Disease Market Barriers<\/p>\n<p style=\"text-align: justify;\">20. Appendix<\/p>\n<p style=\"text-align: justify;\">21. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">22. Disclaimer<\/p>\n<p style=\"text-align: justify;\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=menkes-disease-market-forecast-2034-fda-approvals-competitive-landscape-usd-79-million-market-size-in-2023-177-diagnosed-cases-clinical-pipeline-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +14699457679<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=menkes-disease-market-forecast-2034-fda-approvals-competitive-landscape-usd-79-million-market-size-in-2023-177-diagnosed-cases-clinical-pipeline-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Menkes Disease Market Menkes Disease companies working in the market are Cyprium Therapeutics and Sentynl Therapeutics, and others. In 2023, the Menkes disease market remained limited in size but demonstrated steady progression. The United States dominated the 7MM, contributing close &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/menkes-disease-market-forecast-2034-fda-approvals-competitive-landscape-usd-79-million-market-size-in-2023-177-diagnosed-cases-clinical-pipeline-delveinsight_793322.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,413],"tags":[],"class_list":["post-793322","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/793322","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=793322"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/793322\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=793322"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=793322"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=793322"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}